Curevo Stock

Curevo is a clinical-stage biotech firm that focuses on producing vaccines.

Sign up today and learn more about Curevo Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Curevo Stock

Curevo is a clinical-stage biotech firm focused on producing vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90-subject trial). Results are showing a promising safety profile and the desired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.

Funding History

January 2022$60.0M
November 2022$26.0M

Management

CEO

George Simeon

Chief Medical Officer

Guy De La Rosa

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo